文献速递神经肿瘤

胶质母细胞瘤患者血浆蛋白纵向分析揭示放化疗相关变化

Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy.
PubMed 文献 · J Neurooncol · 2026-10-31

本研究对11例术后胶质母细胞瘤患者和15例健康对照进行纵向血浆蛋白组学分析,使用NULISAseq CNS panel检测131种蛋白。结果显示基线时GBM血浆神经轴索和胶质损伤标志物升高,放疗联合替莫唑胺后细胞因子IL10、IL5、IL33升高而BDNF下降,辅助TMZ减弱放疗诱导的细胞因子升高并降低神经元损伤标志物。

要点

  • 基线GBM血浆神经轴索和胶质损伤及炎症标志物较健康对照升高
  • 放疗联合TMZ后IL10、IL5、IL33升高提示系统性免疫激活
  • 辅助TMZ减弱放疗诱导的细胞因子升高并降低神经元损伤标志物

核心结论

  • 高灵敏度血浆蛋白组学提示GBM治疗诱导CNS特异性和免疫标志物变化,候选标志物可进一步开发用于实时监测治疗反应。

研究设计与样本

  • 对术后GBM患者(n=11)在基线(放疗前)、放疗联合TMZ后和辅助TMZ后纵向采集血浆,与健康对照(n=15)比较,使用NULISAseq CNS panel检测131种蛋白。

主要发现

  • 基线时GBM血浆神经轴索和胶质损伤标志物、细胞外基质调节因子和炎症信号较对照升高。
  • 放疗联合TMZ后IL10、IL5、IL33升高,BDNF轻度下降。
  • 辅助TMZ减弱放疗诱导的细胞因子升高并降低神经元损伤标志物。
  • 纵向分析确认特定蛋白在基线、放疗和TMZ阶段动态变化。

临床怎么用

  • 候选循环标志物可能补充影像学用于监测GBM疾病生物学和治疗反应。

局限性

  • 样本量小(GBM n=11,对照n=15),需在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is the most aggressive primary brain tumor with poor outcomes despite surgery, radiotherapy (RT), and temozolomide (TMZ). Monitoring relies on imaging, which is confounded by pseudoprogression and provides limited molecular insight. Circulating biomarkers may offer a minimally invasive approach to track disease and treatment effects. METHODS: We performed targeted longitudinal proteomic profiling of plasma from post-surgery GBM patients (n = 11) at baseline (pre-radiotherapy (RT)), after RT with concomitant TMZ, and after adjuvant TMZ, alongside healthy controls (n = 15), using the NULISAseq CNS panel covering 131 proteins related to neurodegeneration, neuroinflammation, and vascular health. Differential expressions were assessed using volcano plots, hierarchical clustering, paired statistical comparisons and longitudinal trends analysis. RESULTS: At baseline, GBM plasma showed elevated markers of neuroaxonal and glial injury, extracellular matrix regulators, and inflammatory signaling compared to controls. Several established neurodegeneration and Alzheimer's disease- related biomarkers were also higher in GBM plasma versus controls. Following radiotherapy and concomitant TMZ, cytokines including IL10, IL5, and IL33 increased, indicating systemic immune activation, while BDNF showed a modest decline. Adjuvant TMZ treatment attenuated radiotherapy-induced cytokine elevations and reduced neuronal injury markers, suggesting therapy-driven reduction of inflammatory and neurodegenerative signals. Longitudinal analysis confirmed dynamic shifts in specific proteins across baseline, radiotherapy, and TMZ phases. CONCLUSION: High-sensitivity plasma proteomics suggested therapy-induced changes in CNS-specific and immune markers in GBM, highlighting candidate biomarkers that can be further developed for real-time monitoring of treatment response. These findings suggest candidate circulating markers that may complement imaging for monitoring disease biology and therapeutic response, and warrant validation in larger cohorts.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Kumar A, He Y, Kim S, et al. Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy. J Neurooncol. 2026. PMID: 42965578. doi:10.1007/s11060-026-05839-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。